Venture capital funds in Latin America have overlooked biotech, leaving an untapped opportunity for local capital markets and US and European investors alike. Chilean entrepreneur Cristian Hernandez, founder of newly launched boutique VC Zentynel Frontier Investments, explains how business – and society – can benefit from launching biotech start-ups able to serve a global market at lower cost.

New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside. 

New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.  Its commercial impact is considerable: over the past two decades, private-sector VC’s have invested more than $2bn in UCLA-backed innovations, with 26 start-ups launched through the university in 2019 alone. Amir Naiberg, UCLA’s point man on technology transfer, explains the factors that have made the university a successful advocate for partnerships that produce results for patients.